This comprehensive article explores the evolution, clinical evidence, and positioning of drug-coated balloon dilation (Optilume) for benign prostatic hyperplasia (BPH). The paclitaxel-coated balloon technology represents a significant advance over earlier balloon dilation attempts by preventing tissue regrowth. Clinical evidence demonstrates durable symptom improvement with 67.5% of patients showing 30% or greater IPSS improvement at 24 months without retreatment. This office-based procedure preserves sexual function while delivering significant improvement in urinary flow rates. The article analyzes available data, compares Optilume with other treatment options, and discusses its positioning within the BPH treatment spectrum.